Clinical Trial Update: Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia [Phase 2]

View source ↗

Summary

Phase 2 study of PEG-Intron in hereditary hemorrhagic telangiectasia was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Hereditary Hemorrhagic Telangiectasia
• Hypoxemia
• Liver Disease

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Mayo Clinic | Conditions: Anemia, Liver Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-01-28